Physician profile
Durga Mainaly
NPI 1356049753
$1,934.16
in general payments reported to CMS, 2019-2025
24 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $428 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $286.58 | 2024-2025 | Rystiggo, Briviact, Fintepla |
| Abbvie INC. | $252.95 | 2025 | |
| Sk Life Science, INC. | $189.67 | 2024-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $185.34 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $147.10 | 2025 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $116.11 | 2025 | |
| Eisai INC. | $104.52 | 2024-2025 | |
| Genentech USA, INC. | $77.33 | 2024-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $76.44 | 2025 | Nuplazid |
| Biogen, INC. | $65.72 | 2025 | Leqembi, Skyclarys |
| Neurelis, INC. | $63.35 | 2024-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $56.87 | 2024 | Motpoly Xr |
| Argenx US, INC. | $50.72 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $42.65 | 2025 | Crexont |
| Amgen INC. | $42.49 | 2024-2025 | Uplizna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $28.47 | 2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $25.15 | 2025 | Hyqvia |
| Lilly USA, LLC | $20.87 | 2025 | Kisunla |
| Ge Healthcare | $19.63 | 2025 | |
| Tanabe Pharma America, INC. | $17.87 | 2025 | Radicava |
| Otsuka America Pharmaceutical, INC. | $17.06 | 2025 | Rexulti |
| Lundbeck LLC | $16.87 | 2025 | Vyepti |
| Pfizer INC. | $15.35 | 2025 | |
| Grifols USA, LLC | $15.05 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Durga Mainaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.